A multicenter, multinational Phase 3 Casppian study will evaluate the efficacy and safety of leuprolide mesylate (FP-001) 42 mg controlled-release in patients with CPP. Gonadotropin-releasing ...

Debiopharm Group™ has announced that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg. Debiopharm is ...